New targets and non-cytotoxics in ovarian cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Eisenhauer, E A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CASPASE; CETUXIMAB; DEATH RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; GEFITINIB; INHIBITOR OF APOPTOSIS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATUZUMAB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RAD 001C; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG TARGETING; EARLY DIAGNOSIS; ENZYME INHIBITION; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; MOLECULAR BIOLOGY; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, GROWTH FACTOR;

EID: 33749588792     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl268     Document Type: Article

References (36)

1. Ransohoff DF. Lessons from controversy: Ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005; 97: 315-319.
2. duBols A, Quinn M, Thigpen T et al. 2004 Consensus statement on the management of ovarian cancer: Final document of the 3rd international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG 2004). Ann Oncol 2005; 16 (Suppl 8): Viii7-viii12.
3. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349.
4. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
5. Crijns APG, Boezen HM, Schouten JP et al. Prognostic factors in ovarian cancer; current evidence and future prospects. Eur J Cancer 2003; 1 (S6): 127-143.
6. Rasila KK, Burger RA, Smith H et al. Angiogenesis in gynecological oncology - mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer 2005; 15: 710-726.
7. Link CJ, Kohn E, Reed E. The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: Epidemiologic, pathologic and molecular aspects. Gynecol Oncol 1996; 60: 347-354.
8. Burger RA, Sill M, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 2005; 23 (Suppl 16): 457s (Abstract 5009).
9. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-478.
10. Wilhelm S, Carter C, Tang LY et al. BAY 43-9006 exhibits broad spectrum anti-tumour activity and targets Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis Clin Cancer Res 2003; 9 (Suppl): A78.
11. Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-4400.
12. Motzer RJ, Dror Michaelson M, Redman BG et al. Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patents with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
13. Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of rat kinase and VEGFR inhibitor sorafenib (Bay 43-9006) in patents with advanced renal cell carcinoma (RCC). J Clin Oncol 2005; 23 (16S): 380s.
14. Fischer-Colbrie J, Witt A, Heinzl H et al. EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients. Anticancer Res 1997; 17: 613-619.
15. Schilder RJ, Sill MW, Chen X et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group Study. Clin Cancer Res 2005; 11: 5539-5548.
16. Gordon AN, Finkler N, Edwards RP et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. Int J Gynecol Cancer 2005; 15: 785-792.
17. Saltz LB, Meropol NJ, Loehrer PJ Sr et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
18. Bonner JA, Giralt J, Harari PM et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of the head and neck: A phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 2004 ASCO Annual Meedng Proceedings (Post-Meeting Edition) 2004; 22(14S): 5507.
19. Seiden M, Burris HA, Matulonis U et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subject with heavily pretreated and platinum-resistant advanced Müllerian malignancies. J Clin Oncol 2005; 23(16S); Abstract 3151.
20. Hennessy BT, Smith DL, Ram PT et al. Exploiting the P13K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
21. Altomare DA, Wang HO, Skele KL et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004; 23: 5853-5857.
22. Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans 2004; 32: 393-396.
23. Oza A, Elit L, Biagi J et al. A phase II study of temsirolimus (CCI-779) in patents with metastatic and/or locally advanced recurrent endometrial cancer - NCIC CTG IND160 [abstract]. Clin Cancer Res 2005; 11 (24S); 9099s.
24. Ghobrial IM, Witzig TE, Adjel AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-194.
25. Hotte SJ, Hirte HW, Chen EX et al. HGS-ETR1, a fully human monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: results of a phase I trial. J Clin Oncol 2005; 23(16S); abstract 3052.
26. Deveraux OL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239-252.
27. Wagenknecht B, Glaser T, Naumann U et al. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma. Cell Death Differ. 1999: 6: 370-376.
28. Tamm I, Komblau SM, Segall H et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
29. Lacasse EC, Kandimalla ER, Winocour P et al. Application of XIAP Antisense to cancer and other proliferative disorders: Development of AEG35156/GEM(R)640. Ann N Y Acad Sci 2005; 1058: 215-234.
30. Wang Z, Cuddy M, Samuel T et al. Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J Biol Chem 2004; 279: 48168-48176.
31. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60: 170-176.
32. Miyake H, Nelson C, Rennie PS, Gleave ME. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res 2000; 60: 2547-2554.
33. Zhang H, Kim JK, Edwards CA et al. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005; 7: 909-915.
34. Zellweger T, Miyake H, Cooper S et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-0-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 2001; 298: 934-940.
35. Chi KN, Eisenhauer E, Fazli L et al. A phase I pharmacokinetic and pharmacodynamic; study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patents with localized prostate cancer. J Natl Cancer Inst 2005; 97: 1287-1296.
36. Chi K, Eisenhauer E, Siu L et al. A phase I study of a second generation antisense oligonucleotide to clusterin (DGX-011) in combination with docetaxel: NCIC CTG IND.154. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 2005; 23 (16S): 213s.